GCIA
TERN

Gabelli & Co Investment Advisers’s Terns Pharmaceuticals TERN Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.8M Buy
+205,700
New +$8.45M 1.61% 19

Other funds holding TERN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Gabelli & Co Investment Advisers's TERN Position: Q1 2026 in Review

Gabelli & Co Investment Advisers opened a new position in Terns Pharmaceuticals (TERN) in Q1 2026: 205,700 shares worth $10.8M. The stake represents 1.61% of the portfolio and ranks #19 among its holdings.

317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • Gabelli & Co Investment Advisers held 205,700 shares of Terns Pharmaceuticals worth $10.8M as of Q1 2026.
  • Terns Pharmaceuticals was a new Gabelli & Co Investment Advisers position in Q1 2026.
  • Terns Pharmaceuticals made up 1.61% of Gabelli & Co Investment Advisers's portfolio in Q1 2026, its #19 holding.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Gabelli & Co Investment Advisers's 13F filing for Q1 2026, filed 14 May 2026.